Creek Drive Management Group LLC Takes $3.69 Million Position in Roivant Sciences Ltd. $ROIV

Creek Drive Management Group LLC bought a new position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) in the 4th quarter, Holdings Channel reports. The fund bought 170,000 shares of the company’s stock, valued at approximately $3,689,000. Roivant Sciences makes up 2.6% of Creek Drive Management Group LLC’s holdings, making the stock its 13th biggest position.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in ROIV. Oregon Public Employees Retirement Fund increased its position in Roivant Sciences by 0.6% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 87,152 shares of the company’s stock valued at $1,891,000 after acquiring an additional 500 shares during the period. Bank of Montreal Can lifted its position in Roivant Sciences by 1.3% during the 4th quarter. Bank of Montreal Can now owns 40,012 shares of the company’s stock worth $868,000 after acquiring an additional 516 shares during the period. Allworth Financial LP lifted its position in Roivant Sciences by 48.1% during the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after acquiring an additional 583 shares during the period. Fifth Third Bancorp grew its stake in shares of Roivant Sciences by 15.8% in the 4th quarter. Fifth Third Bancorp now owns 4,310 shares of the company’s stock valued at $94,000 after purchasing an additional 588 shares during the last quarter. Finally, Utah Retirement Systems grew its stake in shares of Roivant Sciences by 3.0% in the 3rd quarter. Utah Retirement Systems now owns 20,626 shares of the company’s stock valued at $312,000 after purchasing an additional 600 shares during the last quarter. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Roivant Sciences Stock Performance

Shares of ROIV opened at $31.43 on Friday. The stock’s 50 day moving average is $29.23 and its two-hundred day moving average is $26.33. Roivant Sciences Ltd. has a twelve month low of $10.70 and a twelve month high of $32.79. The firm has a market capitalization of $22.61 billion, a PE ratio of -52.38 and a beta of 1.13.

Roivant Sciences (NASDAQ:ROIV) last issued its earnings results on Wednesday, May 20th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.57. The business had revenue of $2.52 million during the quarter, compared to the consensus estimate of $3.41 million. Roivant Sciences had a negative return on equity of 20.54% and a negative net margin of 3,629.19%.During the same period in the prior year, the business posted ($0.29) EPS. On average, sell-side analysts predict that Roivant Sciences Ltd. will post -1.83 EPS for the current year.

Insider Buying and Selling

In related news, CAO Jennifer Humes sold 13,538 shares of the company’s stock in a transaction on Wednesday, April 8th. The stock was sold at an average price of $28.37, for a total transaction of $384,073.06. Following the transaction, the chief accounting officer owned 84,191 shares of the company’s stock, valued at $2,388,498.67. This represents a 13.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Matthew Gline sold 289,774 shares of the stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $29.16, for a total value of $8,449,809.84. Following the completion of the transaction, the chief executive officer owned 16,736,116 shares of the company’s stock, valued at $488,025,142.56. The trade was a 1.70% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 703,312 shares of company stock valued at $20,805,883 over the last quarter. Company insiders own 10.80% of the company’s stock.

Analyst Ratings Changes

ROIV has been the topic of a number of recent research reports. Sanford C. Bernstein started coverage on Roivant Sciences in a report on Friday, March 20th. They issued an “outperform” rating and a $35.00 target price on the stock. Guggenheim increased their price target on Roivant Sciences from $30.00 to $36.00 and gave the stock a “buy” rating in a report on Tuesday, May 26th. Jefferies Financial Group reiterated a “buy” rating on shares of Roivant Sciences in a research report on Tuesday, March 3rd. TD Cowen boosted their price objective on shares of Roivant Sciences from $38.00 to $41.00 and gave the company a “buy” rating in a research note on Thursday, May 21st. Finally, Weiss Ratings downgraded shares of Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a research report on Friday, May 22nd. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $33.59.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.